Wed, September 21, 2011
Tue, September 20, 2011
Mon, September 19, 2011
Sun, September 18, 2011
Sat, September 17, 2011
Fri, September 16, 2011
Thu, September 15, 2011
Wed, September 14, 2011
Tue, September 13, 2011
Mon, September 12, 2011
Sun, September 11, 2011
Sat, September 10, 2011
Fri, September 9, 2011
Thu, September 8, 2011
Wed, September 7, 2011
Tue, September 6, 2011
Mon, September 5, 2011
Sun, September 4, 2011
Sat, September 3, 2011
Fri, September 2, 2011
Thu, September 1, 2011
Wed, August 31, 2011
Tue, August 30, 2011
[ Tue, Aug 30th 2011 ] - Market Wire
00 a.m. ET
Mon, August 29, 2011
Fri, August 26, 2011
Thu, August 25, 2011
Wed, August 24, 2011
Tue, August 23, 2011
Mon, August 22, 2011

Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference


//health-fitness.news-articles.net/content/2011/ .. nley-global-healthcare-unplugged-conference.html
Published in Health and Fitness on by Market Wire   Print publication without navigation


Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference -- SAN DIEGO, Sept. 7, 2011 /PRNewswire/ --

Amylin Pharmaceuticals to Present at the Morgan Stanley Global Healthcare Unplugged Conference

[ ]

SAN DIEGO, Sept. 7, 2011 /PRNewswire/ -- Amylin Pharmaceuticals, Inc. (Nasdaq: [ AMLN ]) will be presenting at the Morgan Stanley Global Healthcare Unplugged Conferenceon Wednesday, September 14, 2011 at 1:35 p.m. ET / 10:35 a.m. PT in New York. Daniel M. Bradbury, president and chief executive officer, Amylin Pharmaceuticals, will provide a corporate overview.

The presentation will be webcast live through the "Investors" section of Amylin's corporate website at [ www.amylin.com ], and a recording will be made available on the website following the event. To access the live webcast, please log on to Amylin's site approximately fifteen minutes prior to the presentation to register and download any necessary audio software.

About Amylin Pharmaceuticals

Amylin Pharmaceuticals is a biopharmaceutical company dedicated to improving lives of patients through the discovery, development and commercialization of innovative medicines. Amylin has developed and gained approval for two first-in-class medicines for diabetes, SYMLIN® (pramlintide acetate) injection and BYETTA® (exenatide) injection. Amylin's research and development activities leverage the Company's expertise in metabolism to develop potential therapies to treat diabetes and obesity. Amylin is headquartered in San Diego, California and has a commercial manufacturing facility in Ohio. Further information about Amylin Pharmaceuticals is available at [ www.amylin.com ].

SOURCE Amylin Pharmaceuticals, Inc.

[ Back to top ]

RELATED LINKS
[ http://www.amylin.com ]


Publication Contributing Sources